AbelZeta to Attend 43rd Annual J.P. Morgan Healthcare Conference and Join Panel at 8th Annual BFC Healthcare Conference
ROCKVILLE, MD, December 23, 2024 – AbelZeta Pharma, Inc. (“AbelZeta” or the “Company”), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, will attend the 43rd Annual J.P. Morgan Healthcare Conference on January 13-16, 2025, in San Francisco, CA, and host meetings showcasing the Company’s recent accomplishments and sharing strategic plans moving forward. The Company’s Chairman and CEO, Tony (Bizuo) Liu, has also been invited as a panel speaker at the 8th Annual BFC Global Healthcare BD and Investment Conference on Sunday, January 12, 2025.
Session: Faith to Incubate: Global Biotech Investment Trends and Focus
Time & Date: January 12, 2025, 09:15 – 10:15 PST
Location: The St. Regis San Francisco
Registration: http://2025sf.bfcconference.com/
About AbelZeta Pharma, Inc.
AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body’s own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases. AbelZeta advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies, with a pipeline comprised of CAR-T and TIL therapies.
Forward-Looking Statements
Company Contact:
Sarah Kelly
Director of Communications
AbelZeta Pharma Inc.
Phone: +1 (240) 552 5870
Email: [email protected]